Circadian Rhythm in Dihydropyrimidine Dehydrogenase Activity and Reduced Glutathione Content in Peripheral Blood of Nasopharyngeal Carcinoma Patients

References

• Bélanger P. M., Labrecque G. Biological rhythms in hepatic drug metabolism and biliary systems. Biologic Rhythms in Clinical and Laboratory Medicine, Y. Touitou, E. Haus. Springer‐Verlag, Berlin, Heidelberg, New York 1992; 403–409
   Google Scholar
• Eriguchi M., Lévi F., Hisa T., Yanagie H., Nonaka Y., Takeda Y. Chronotherapy for cancer. Biomed. Pharmacother. 2003; 57(Suppl 1)92s–95s
   Google Scholar
• Fleming R. A., Milano G., Thyss A., Etienne M. C., Renee N., Schneider M., Demard F. Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients. Cancer Res. 1992; 52: 2899–2902
   PubMed Web of Science ®Google Scholar
• Gamelin E., Boisdron‐Celle M., Larra F., Robert J. A simple chromatographic method for the analysis of pyrimidines and their dehydrogenated metabolites. J. Liq. Chrom. Rel. Technol. 1997; 20: 3155–3172
   Web of Science ®Google Scholar
• Garg M. B., Sevester J. C., Sakoff J. A., Ackland S. P. Simple liquid chromatographic method for the determination of uracil and dihydrouracil plasma levels: a potential pretreatment predictor of 5‐fluorouracil toxicity. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2002; 774: 223–230
   PubMed Web of Science ®Google Scholar
• Gonzalez F. J., Fernandez‐Salguero P. Diagnostic analysis clinical importance and molecular basis of dihydropyrimidine dehydrogenase deficiency. Trends Pharmacol. Sci. 1995; 16: 325–327
   PubMed Web of Science ®Google Scholar
• Grem J. L., Yee L. K., Venzon D. J., Takimoto C. H., Allegra C. J. Inter‐ and intraindividual variation in dihydropyrimidine dehydrogenase activity in peripheral blood mononuclear cells. Cancer Chemother. Pharmacol. 1997; 40: 117–125
   PubMed Web of Science ®Google Scholar
• Harris B. E., Song R., Soong S., Diasio R. B. Relationship between dihydropyrimidine dehydrogenase activity and plasma 5‐fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5‐fluorouracil by protracted continuous infusion. Cancer Res. 1990; 50: 197–201
   PubMed Web of Science ®Google Scholar
• Harris B. E., Carpenter J. T., Diasio R. B. Severe 5‐fluorouracil toxicity secondary to dihydropyrimidine dehydrogenase deficiency: a potentially more common pharmacogenetic syndrome. Cancer 1991; 68: 499–501
   PubMed Web of Science ®Google Scholar
• Heggie G. D., Sommadossi J. P., Cross D. S., Huster W. J., Diasio R. B. Clinical pharmacokinetics of 5‐fluorouracil and its metabolites in plasma, urine and bile. Cancer Res. 1987; 47: 2203–2206
   PubMed Web of Science ®Google Scholar
• Ishikawa Y., Kubota T., Otani Y., Watanabe M., Teramoto T., Kumai K., Kitajima M., Takechi T., Okabe H., Fukushima M. Dihydropyrimidine dehydrogenase activity and messenger RNA level may be related to the antitumor effect of 5‐fluorouracil on human tumor xenografts in nude mice. Clin. Cancer Res. 1999; 5: 883–889
   PubMed Web of Science ®Google Scholar
• Johnson M. R., Hageboutros A., Wang K., High L., Smith J. B., Diasio R. B. Life‐threatening toxicity in a dihydropyrimidine dehydrogenase deficient patient after treatment with topical 5‐fluorouracil. Clin. Cancer Res. 1999; 5: 2006–2011
   PubMed Web of Science ®Google Scholar
• Lévi F. Cancer Chronotherapy. J. Pharm. Pharmcol. 1999; 51: 891–898
   PubMed Web of Science ®Google Scholar
• Lévi F., Zidani R., Misset J. L. for the International Organization for Cancer Chronotherapy Randomized multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. Lancet 1997; 350: 681–686
   PubMed Web of Science ®Google Scholar
• Lévi F., Zidani R., Brienza S., Dogliotti L., Perpoint B., Rotarski M., Letourneau Y., Llory J. F., Chollet P., Le Rol A., Focan C. A multicenter evaluation of intensified, ambulatory, chronomodulated chemotherapy with oxaliplatin, 5‐fluorouracil, and leucovorin as initial treatment of patients with metastatic colorectal carcinoma. Cancer 1999; 85: 2532–2540
   PubMed Web of Science ®Google Scholar
• Li X. M., Metzger G., Filipskl E., Boughattas N., Lemaigre G., Hecquet B., Filipski J., Levi F. Pharmacologic modulation of reduced glutathione circadian rhythms with buthionine sulfoximine: relationship with Cisplatin toxicity in mice. Toxicol. Appl. Pharm. 1997; 143: 281–290
   PubMed Web of Science ®Google Scholar
• Lowry O. H., Rosebrough N. J., Farr A. L., Randall R. J. Protein measurement with the Folin Phenol reagent. J. Biol. Chem. 1951; 193: 265–275
   PubMed Web of Science ®Google Scholar
• Meister A. Glutathione metabolism and its selective modification. J. Biol. Chem. 1988; 263: 17205–17508
   PubMed Web of Science ®Google Scholar
• Mormont M. C., Lévi F. Circadian‐system alterations during cancer processed: a review. Int. J. Cancer 1997; 70: 241–247
   PubMed Web of Science ®Google Scholar
• Mormont M. C., Lévi F. Cancer chronotherapy: Principles, applications and perspectives. Cancer 2003; 97: 155–169
   PubMed Web of Science ®Google Scholar
• Mormont M. C., Hecquet B., Bogdan A., Benavides M., Touitou Y., Lévi F. Non‐invasive estimation of the circadian rhythm in serum cortisol in patients with ovarian or colorectal cancer. Int. J. Cancer 1998; 78: 421–424
   PubMed Web of Science ®Google Scholar
• Mormont M. C., Langouet A. M., Claustrat B., Bogdan A., Marion S., Waterhouse J., Touitou Y., Lévi F. Marker rhythms of circadian system function: a study of patients with metastatic colorectal cancer and good performance status. Chronobiol Int. 2002a; 19: 141–155
   PubMed Web of Science ®Google Scholar
• Mormont M. C., Bogdan A., Cormont S., Touitou Y., Lévi F. Cortisol diurnal variation in blood and saliva of patients with metastatic colorectal cancer: relevance for clinical outcome. Anticancer Res. 2002b; 22: 1243–1250
   PubMed Web of Science ®Google Scholar
• Porsin B., Formento J. L., Filipski E., Etienne M. C., Francoual M., Renee N., Magne N., Lévi F., Milano G. Dihydropyrimidine dehydrogenase circadian rhythm in mice liver: comparison between enzyme activity and gene expression. Eur. J. Cancer 2003; 39: 822–828
   PubMed Web of Science ®Google Scholar
• Smaaland R., Svardal A. M., Lote K., Ueland M., Laerum O. D. Glutathione content in human bone marrow and circadian stage relation to DNA synthesis. J. Natl. Cancer Inst. 1991; 83: 1092–1098
   PubMed Web of Science ®Google Scholar
• Svardal A. M., Mansoor M. A., Ueland P. M. Determination of reduced, oxidized, and protein‐bound glutathione in human plasma with precolumn derivatization with monobromobimane and liquid chromatography. Anal. Biochem. 1990; 184: 338–346
   PubMed Web of Science ®Google Scholar
• Touitou Y., Portaluppi F., Smolensky M. H., Rensing L. Ethical principles and standards for the conduct of human and animal biological rhythm research. Chronobiol. Int. 2004; 21: 161–170
   PubMed Web of Science ®Google Scholar
• Tuchman M., Roemeling R. V., Lanning R. M., Sothern R. B., Hrushesky W. J.M. Sources of variability of dihydropyrimidine dehydrogenase activity in human blood mononuclear cells. Ann. Rev. Chronopharmacol. 1989; 5: 399–402
   Google Scholar
• Uhlig S., Wendel A. The physiological consequences of glutathione variations. Life Sci. 1992; 51: 1083–1094
   PubMed Web of Science ®Google Scholar
• White B. P., Davies M. H., Schnell R. C. Circadian variations in hepatic glutathione content, gammaglutamylcysteine synthetase and gamma‐glutamyl transferase activities in mice. Toxicol. Lett. 1987; 35: 217–223
   PubMed Web of Science ®Google Scholar
• Woodcock T. M., Martin D. S., Damin L. A., Kemeny N. E., Young C. W. Combination clinical trials with thymidine and fluorouracil: a phase I and clinical pharmacological evaluation. Cancer 1980; 45(5 Suppl)1135–1143
   PubMed Web of Science ®Google Scholar
• Xian L. J., Sun J., Cao Q. Y., Ye Y. L., Liu X. H., Li X. M., Lévi F. Circadian Rhythms of DNA Synthesis in Nasopharyngeal Carcinoma Cells. Chronobiol. Int. 2002; 19: 69–76
   PubMed Web of Science ®Google Scholar
• Zeng Z. Y., Xu G. P. Nasopharyngeal carcinoma. Clinical Oncology, D. S. Wan. Science Public, BeijingChina 1999; 122–132
   Google Scholar
• Zidan J., Kuten A., Robinson E. Intensive short course chemotherapy followed by radiotherapy of locally advanced nasopharyngeal carcinoma. Cancer 1996; 77: 1973–77
   PubMed Web of Science ®Google Scholar